Avalon GloboCareALBT
About: Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Employees: 5
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
4% more capital invested
Capital invested by funds: $52K [Q3] → $54K (+$1.92K) [Q4]
0.04% less ownership
Funds ownership: 1.57% [Q3] → 1.53% (-0.04%) [Q4]
47% less funds holding
Funds holding: 15 [Q3] → 8 (-7) [Q4]
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for ALBT.
Financial journalist opinion
Based on 4 articles about ALBT published over the past 30 days








